The Addenbrooke’s Cognitive Examination III (ACE-III): linguistic and cultural adaptation into Russian
- Authors: Varako N.A.1,2,3, Arkhipova D.V.1, Kovyazina M.S.1,2,3, Yusupova D.G.2, Zaytsev A.B.4, Zimin A.A.2, Solomina A.V.5, Bundhun P.6, Ramchandani N.M.7, Suponeva N.A.2, Piradov M.A.2
-
Affiliations:
- Lomonosov Moscow State University
- Research Center of Neurology
- Psychological Institute of Russian Academy of Education
- Sechenov First Moscow State Medical University
- Association for Contextual Behavioral Science
- Victoria Hospital
- Kenyatta National Hospital
- Issue: Vol 16, No 1 (2022)
- Pages: 53-58
- Section: Technologies
- URL: https://journals.rcsi.science/2075-5473/article/view/124082
- DOI: https://doi.org/10.54101/ACEN.2022.1.7
- ID: 124082
Cite item
Full Text
Abstract
Introduction. Timely identification of cognitive impairment is very important, with standardized screening instruments required to assess the cognitive status. However, the arsenal of such screening scales available to clinicians in Russia is limited and requires expansion. According to numerous international studies, the Addenbrooke’s Cognitive Examination III (ACE-III) has the necessary sensitivity and specificity, which speaks well for developing and validating a Russian language version.
The aim of the study was the linguistic and cultural adaptation of the Addenbrooke’s Cognitive Examination III (ACE-III).
Materials and methods. A forward and back translation was performed of three versions of the scale and the scoring guidelines. A preliminary version of the ACE-III was developed, pilot testing of the preliminary version was conducted, and a final Russian language version was then developed with the help of a philologist/linguist, and experts in neuropsychology and neurology, who work specifically with patients with cognitive impairments. Pilot testing of the preliminary version of the ACE-III involved 16 neurological patients at the Research Center of Neurology and the Pirogov National Medical and Surgical Centre, who were aged 37–74 (60.25 ± 10.8) years and 56% of whom were women. The patients’ clinical condition corresponded to the diagnostic criteria for cerebrovascular disease (n = 12), Parkinson's disease (n = 3) and spinocerebellar ataxia (n = 1).
Results. Neither the subjects nor the examiners had any difficulty in understanding the instructions or the content during testing. Further work was done based on the results of the pilot testing, and three final versions of the scale (A, B and C) were accepted, as well as the scoring guidelines, a link to which is provided in the article.
Conclusion. The obtained results indicate that the developed version of the ACE-III can be understood by the Russian-speaking population and can be used in clinical practice. At the time of article publication, research is being conducted to assess the psychometric properties of the final Russian language version.
Full Text
##article.viewOnOriginalSite##About the authors
Natalia A. Varako
Lomonosov Moscow State University; Research Center of Neurology; Psychological Institute of Russian Academy of Education
Author for correspondence.
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-8310-8169
Cand. Sci. (Psychol.), senior researcher, Methodology of psychology chair, Faculty of psychology, senior researcher, Department of neurorehabilitation and physiotherapy, senior researcher, Laboratory of counseling psychology and psychotherapy
Russian Federation, Moscow; Moscow; MoscowDaria V. Arkhipova
Lomonosov Moscow State University
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0003-0637-6044
master student, Faculty of psychology
Russian Federation, MoscowMaria S. Kovyazina
Lomonosov Moscow State University; Research Center of Neurology; Psychological Institute of Russian Academy of Education
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-1795-6645
D. Sci. (Psychol.), Assoc. Prof., Corr. Member of the Russian Academy of Education, Professor, Neuro and pathopsychology chair, Faculty of psychology, researcher, Department of neurorehabilitation and physiotherapy, acting Head, Laboratory of counseling psychology and psychotherapy
Russian Federation, Moscow; Moscow; MoscowDjamilya G. Yusupova
Research Center of Neurology
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-5826-9112
neurologist, junior researcher, Department of neurorehabilitation and physiotherapy
Russian Federation, MoscowAleksander B. Zaytsev
Sechenov First Moscow State Medical University
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0003-3774-3070
Cand. Sci. (Philology), Assoc. Prof., Institute of Linguistics and Intercultural Communication
Russian Federation, MoscowAleksey A. Zimin
Research Center of Neurology
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-9226-2870
Cand. Sci. (Pedagogy), senior researcher, Department of neurorehabilitation and physiotherapy
Russian Federation, MoscowAnastasiia V. Solomina
Association for Contextual Behavioral Science
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-0069-1791
psychologist, translator, member of Association for Contextual Behavioral Science
United States, Jenison, MichiganPratish Bundhun
Victoria Hospital
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0003-4680-9297
junior researcher, Department of neurorehabilitation and physiotherapy
Mauritius, CandosNicha M. Ramchandani
Kenyatta National Hospital
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0001-9129-7118
junior researcher, Department of neurorehabilitation and physiotherapy
Kenya, NairobiNataliya A. Suponeva
Research Center of Neurology
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0003-3956-6362
D. Sci. (Med.), Corr. Member of the Russian Academy of Sciences, Head, Department of neurorehabilitation and physiotherapy
Russian Federation, MoscowMikhail A. Piradov
Research Center of Neurology
Email: annaly-nevrologii@neurology.ru
ORCID iD: 0000-0002-6338-0392
D. Sci. (Med.), Professor, Full Member of the Russian Academy of Sciences, Director
Russian Federation, MoscowReferences
- Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. PMID: 1202204.
- Nasreddine Z.S., Phillips N.A., Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi: 10.1111/j.1532-5415.2005.53221.x. PMID: 15817019.
- Hsieh S., Schubert S., Hoon C. et al. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36(3–4):242–250. doi: 10.1159/000351671. PMID: 23949210.
- Matias-Guiu J.A., Cortes-Martinez A., Valles-Salgado M. et al. Addenbrooke’s cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests. Int Psychogeriatr. 2017;29(1):105–113. DOI: 10117/S1041610216001496. PMID: 27682860.
- Mathuranath P.S., Nestor P.J., Berrios G.E. et al. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology. 2000;55(11):1613–1620. doi: 10.1212/01.wnl.0000434309.85312.19. PMID: 11113213.
- Noone P. Addenbrooke’s Cognitive Examination-III. Occup Med (Lond). 2015;65(5):418–420. doi: 10.1093/occmed/kqv041. PMID: 26187808.
- Akhutina T.V. Neuropsychological examination. In: Akhutina T.V., Inshakova O.B. (eds.) [Neuropsychological diagnosis, examination of writing and reading of younger schoolboys]. 2nd ed. Moscow, 2012:4–64. (In Russ.)
- Bajpai S., Upadhyay A., Sati H. et al. Hindi version of Addenbrooke’s cognitive examination III: Distinguishing cognitive impairment among older Indians at the lower cut-offs. Clin Interv Aging. 2020;15:329–339. doi: 10.2147/CIA.S244707. PMID: 32184582.
- Hodges J.R., Larner A.J. Addenbrooke’s Cognitive Examinations: ACE, ACE-R, ACE-III, ACEapp, and M-ACE. In: Larner A.J. (ed.) Cognitive Screening Instruments. Practical Approach. Second Edition. Cham: Springer, 2017:109–137. doi: 10.1007/978-3-319-44775-9_6.
- Mekala S., Paplikar A., Mioshi E. et al. Dementia diagnosis in seven languages: Addenbrooke’s Cognitive Examination-III in India. Arch Clin Neuropsychol. 2020; 35(5):528–538. doi: 10.1093/arclin/acaa013/5809061. PMID: 32188967.
- Mioshi E., Dawson K., Mitchell J. et al. The Addenbrooke’s Cognitive Exa- mination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078–1085. doi: 10.1002/gps.1610. PMID: 16977673.
- Elamin M., Holloway G., Bak T.H. et al. The utility of the Addenbrooke’s Cognitive Examination Version Three in early-onset dementia. Dement Geriatr Cogn Disord. 2015;41(1–2):9–15. doi: 10.1159/000439248. PMID: 26473749.
- Kan K.C., Subramaniam P., Shahrizaila N. et al. Validation of the Malay Version of Addenbrooke’s Cognitive Examination III in detecting mild cognitive impairment and dementia. Dement Geriatr Cogn Dis Extra. 2019;9(1):66–76. doi: 10.1159/000495107. PMID: 31043965.
- Stott J., Scior K., Mandy W. et al. Dementia screening accuracy is robust to premorbid IQ variation: evidence from the Addenbrooke’s Cognitive Exa- mination-III and the Test of Premorbid Function. Journal Alzheimers Dis. 2017;57(4):1293–1302. doi: 10.3233/JAD-161218. PMID: 28372334.
- Senda M., Terada S., Takenoshita S. et al. Diagnostic utility of the Addenbrooke’s cognitive examination — III (ACE-III), Mini-ACE, Mini-Mental State Examination, Montreal Cognitive Assessment and Hasegawa Dementia Scale-Revised for detecting mild cognitive impairment and dementia. Psychogeriatrics. 2019;20(2):156–162. doi: 10.1111/psyg.12480. PMID: 31448862.
- Takenoshita S., Terada S., Yoshida H. et al. Validation of Addenbrooke’s cognitive examination III for detecting mild cognitive impairment and dementia in Japan. BMC Geriatr. 2019;19(1):123. doi: 10.1186/s12877-019-1120-4. PMID: 31035933.
- Li X., Yang L., Yin J. et al. Validation study of the Chinese version of Addenbrooke’s Cognitive Examination III for diagnosing mild cognitive impairment and mild dementia. J Clin Neurol. 2019;15(3): 313–320. doi: 10.3988/jcn.2019.15.3.313. PMID: 31286702.
Supplementary files
